Effects of Branched-Chain Amino Acids Supplementation in Patients With Cirrhosis and a Previous Episode of Hepatic Encephalopathy: A Randomized Study

2011 ◽  
Vol 106 (6) ◽  
pp. 1081-1088 ◽  
Author(s):  
Iñigo Les ◽  
Eduardo Doval ◽  
Rita García-Martínez ◽  
Mercè Planas ◽  
Guillermo Cárdenas ◽  
...  
Keyword(s):  
Amino Acids ◽  
Hepatic Encephalopathy ◽  
Randomized Study ◽  
Branched Chain Amino Acids ◽  
Previous Episode ◽  
Branched Chain

Branched-chain amino acids for people with hepatic encephalopathy

2015 ◽  
Author(s):  
Lise Lotte Gluud ◽  
Gitte Dam ◽  
Iñigo Les ◽  
Juan Córdoba ◽  
Giulio Marchesini ◽  
...  
Keyword(s):  
Amino Acids ◽  
Hepatic Encephalopathy ◽  
Branched Chain Amino Acids ◽  
Branched Chain

scholarly journals From mitochondria to healthy aging: The role of branched-chain amino acids treatment: MATeR a randomized study

2020 ◽  
Vol 39 (7) ◽  
pp. 2080-2091 ◽  
Author(s):  
Ilaria Buondonno ◽  
Francesca Sassi ◽  
Giulia Carignano ◽  
Francesca Dutto ◽  
Cinzia Ferreri ◽  
...  
Keyword(s):  
Amino Acids ◽  
Healthy Aging ◽  
Randomized Study ◽  
Branched Chain Amino Acids ◽  
Branched Chain

scholarly journals Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study

Nutrients ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1810 ◽  
Author(s):  
Helen Vidot ◽  
Erin Cvejic ◽  
Liam J. Finegan ◽  
E. Arthur Shores ◽  
David G. Bowen ◽  
...  
Keyword(s):  
Amino Acids ◽  
Hepatic Encephalopathy ◽  
Branched Chain Amino Acids ◽  
Controlled Study ◽  
Intention To Treat ◽  
Cognitive Improvement ◽  
Trail Making ◽  
Branched Chain ◽  
Nutritional Data ◽  
Inhibitory Control Test

Introduction: Hepatic encephalopathy (HE) is common in patients with cirrhosis and is characterised by reduced hepatic ammonia clearance. This is accompanied by alterations in gut bacteria that may be ameliorated with synbiotics (pro- and prebiotics). Branched chain amino acids (BCAAs) are thought to have a role in the detoxification of ammonia. We investigated the effects of the administration of synbiotics and/or BCAAs in treating HE. Methods: Participants with overt HE were randomised in a blinded placebo-controlled study to receive synbiotics, BCAAs, or a combination of BCAAs and Synbiotics. Relevant biochemical and nutritional data and depression and anxiety scores (DASS-21) were collected at entry, 4 weeks, and on completion, at 8 weeks. The Trail Making Test (TMT) and Inhibitory Control Test (ICT) were used to assess cognitive function in patients withHE. Results were analysed using linear mixed effects regression analyses. Results: Sixty-one participants were enrolled and 49 who returned for at least 1 follow-up review were included in the intention to treat analysis. The mean age was 55.8 ± 6.1 years and 86% were males. Despite evidence of a placebo effect, there was significant improvement in TMT B and ICT weighted lures in participants who received combined synbiotics/BCAAs treatment compared to placebo at study completion (p ≤ 0.05). Cognitive improvement occurred without a significant change in ammonia levels. Conclusion: To our knowledge, this is the first study reporting that combined synbiotics and BCAAs improve HE, and that may be beneficial in the management of HE. A larger study is needed to confirm these results.

A systematic review on branched-chain amino acids for hepatic encephalopathy

2001 ◽  
Vol 1 (S3) ◽  
Author(s):  
Bodil Als-Nielsen ◽  
Ronald Koretz ◽  
Lise Lotte Kjaergard ◽  
Christian Gluud
Keyword(s):  
Systematic Review ◽  
Amino Acids ◽  
Hepatic Encephalopathy ◽  
Branched Chain Amino Acids ◽  
Branched Chain
Sign in / Sign up

Export Citation Format

Share Document